Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Subcutaneous Immunoglobulin (SCIG) Market Set To Climb From $16.31 Billion In 2026 To $25.71 Billion By 2030
The subcutaneous immunoglobulin (scig) market has seen substantial expansion in recent years. This market is projected to grow from $14.39 billion in 2025 to $16.32 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.4%. Historically, this expansion is attributable to factors such as an increasing diagnosis of primary immunodeficiency disorders, the limitations inherent in intravenous immunoglobulin therapy, a rising requirement for long-term immune support, the enhanced safety profile of scig, and a growing patient preference for receiving care in a home setting.
The market for subcutaneous immunoglobulin (scig) is projected to experience substantial expansion in the coming years. This market is forecast to reach $25.71 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.0%. This anticipated growth is driven by several factors, including the broadened application of scig beyond immunodeficiency, a heightened emphasis on homecare treatments in healthcare, continuous innovations in infusion technology, the increasing occurrence of autoimmune and neurological conditions, and a rising preference for treatment approaches centered around patients. Key trends anticipated during this period involve a notable transition from intravenous immunoglobulin (IVIG) to scig treatments, an uptick in the usage of immunoglobulin therapy at home, a greater inclination towards devices enabling self-administration, the wider application of scig in managing chronic immune conditions, and an elevated need for sustained immune replacement therapy.
Get A Free Sample Report With In-Depth Market Insights:
Subcutaneous Immunoglobulin (SCIG) Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The expansion of secondary immunodeficiency diseases is anticipated to boost the Subcutaneous Immunoglobulin Market moving forward. These diseases involve a diminished or impaired immune system stemming from causes external to the immune system itself. Factors contributing to the rise in secondary immunodeficiency conditions include aging populations, the application of immunosuppressive therapies, and exposure to environmental toxins. Subcutaneous immunoglobulin treatment delivers antibodies to fortify a compromised immune system, particularly in long-term ailments like HIV or autoimmune diseases, thus preventing infections and aiding immune function during therapy. For instance, in October 2024 according to the HIV i-Base is a UK-based treatment activist organization in 2023, new HIV diagnoses increased by 36% among heterosexual men, rising from 445 in 2022 to 605, and by 30% among heterosexual women, rising from 602 in 2022 to 780. Consequently, the growing prevalence of secondary immunodeficiency diseases is a key driver for the Subcutaneous Immunoglobulin Market’s expansion.
Subcutaneous Immunoglobulin (SCIG) Market Driver: Rising Neurological Disorders Fuel Growth In The Subcutaneous Immunoglobulin Market
Subcutaneous Immunoglobulin (SCIG) Market Breakdown By Product Type And Application
The subcutaneous immunoglobulin (scig) market covered in this report is segmented –
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
Subcutaneous Immunoglobulin (SCIG) Market Innovation Trends Shaping Future Development
Major companies in the subcutaneous immunoglobulin (SCIG) market are prioritizing the development of advanced solutions, such as prefilled, ready-to-use formulations, to enhance the convenience of treatment, support self-administration, and generally improve the patient experience. Ready-to-use SCIG formulations are stable, premeasured immunoglobulin products designed for subcutaneous delivery, which enables patients with primary immunodeficiency and other immune disorders to administer their therapy more easily outside of clinical settings. For example, in April 2023, the U.S. Food and Drug Administration (FDA) approved a 50 mL / 10 g prefilled syringe presentation of Hizentra (Immune Globulin Subcutaneous [Human] 20%), offering patients a simplified, ready-to-use choice that facilitates more convenient home infusion and improves treatment adherence.
Subcutaneous Immunoglobulin (SCIG) Market Company Landscape And Competitive Strategy
Major companies operating in the subcutaneous immunoglobulin (scig) market are CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, Biotest AG, Bio Products Laboratory Ltd., ADMA Biologics Inc., Kamada Pharmaceuticals, Takeda Pharmaceutical Company Limited, Baxter International Inc., Bharat Serums and Vaccines Limited, Emergent BioSolutions Inc., Pfizer Inc., Johnson & Johnson, Lonza Group, Argenx SE, CinnaGen Co., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd.
View The Full Subcutaneous Immunoglobulin (SCIG) Market Report:
Subcutaneous Immunoglobulin (SCIG) Market Regional Analysis And Top Geography
North America was the largest region in the subcutaneous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (scig) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model